In vitro vitamin K(2) and 1α,25-dihydroxyvitamin D(3) combination enhances osteoblasts anabolism of diabetic mice. (Poon CC et al)
Recently published paper in Eur J Pharmacology showed that the combination of vitamins K2 and D3 could be a novel therapeutic strategy in treating diabetes-associated osteoporosis.
In this study, researchers evaluated the anabolic effect and the underlying cellular mechanisms involved of vitamin K2 (10 nM) and 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) (10 nM), alone and in combination, on primary osteoblasts harvested from the iliac crests of C57BL/KsJ lean (+/+) and obese/diabetic (db/db) mice. A lower alkaline phosphatase (ALP) activity plus a reduced expression of bone anabolic markers and bone formation transcription factors (osteocalcin, Runx2, Dlx5, ATF4 and OSX) were consistently detected in osteoblasts of db/db mice compared to lean mice. A significantly higher calcium deposits formation in osteoblasts was observed in lean mice when compared to db/db mice.
Co-administration of vitamin K2 and D3 caused an enhancement of calcium deposits in osteoblasts. Moreover, co-administration of Vitamins K2 and D3 time dependently increased the levels of bone anabolic markers and bone formation transcription factors.
The data showed that combination of vitamin K2 with D3 should have beneficial effect on bone tissue and may be a novel therapeutic strategy in treating osteoporosis.
Reference:
Poon CC, Li RW, Seto SW, Kong SK, Ho HP, Hoi MP, Lee SM, Ngai SM, Chan SW, Leung GP, Kwan YW. In vitro vitamin K(2) and 1α,25-dihydroxyvitamin D(3) combination enhances osteoblasts anabolism of diabetic mice. Eur J Pharmacol. 2015 Nov 15;767:30-40. doi: 10.1016/j.ejphar.2015.09.048. Epub 2015 Oct 8.